- Document Number:
20210267958
- Appl. No:
17/175101
- Application Filed:
February 12, 2021
- نبذة مختصرة :
This application relates to methods of diagnosing and treating anorexia nervosa (AN) and binge eating disorder (BED) with a nonselective activator of metabotropic glutamate receptors (mGluRs).
- Assignees:
The Children's Hospital of Philadelphia (Philadelphia, PA, US)
- Claim:
1.-111. (canceled)
- Claim:
112. A method of treating an eating disorder in a subject comprising administering a nonselective mGluR activator to the subject, wherein the eating disorder is selected from anorexia nervosa (AN) and binge eating disorder (BED), thereby treating AN and/or BED.
- Claim:
113. The method of claim 112, wherein the nonselective mGluR activator is fasoracetam.
- Claim:
114. The method of claim 113, wherein the fasoracetam is fasoracetam monohydrate.
- Claim:
115. The method of claim 113, wherein the fasoracetam is administered at a dose of 50-400 mg and wherein the dose is administered once, twice, or three times daily.
- Claim:
116. The method of claim 113, wherein the fasoracetam is administered at a dose of 100 mg, 200 mg, 300 mg, or 400 mg twice daily.
- Claim:
117. The method of claim 112, wherein the subject has at least one genetic alteration in an mGluR network gene.
- Claim:
118. The method of claim 117, wherein the genetic alteration is a copy number variation (CNV).
- Claim:
119. The method of claim 118, wherein the CNV is a deletion or a duplication.
- Claim:
120. The method of claim 117, wherein at least one of the following applies: (i) the genetic alteration is in at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 30, 40, 50, 60, 70, or all Tier 1 mGluR network genes; (ii) the genetic alteration is in at least 2, 3, 4, 5, 10, 20, 30, 50, 100, 150, 175, or all Tier 2 mGluR network genes; or (iii) the genetic alteration is in at least 2, 3, 4, 5, 10, 20, 50, 100, 200 300, 400, 500, or all Tier 3 mGluR network genes.
- Claim:
121. The method of claim 117, wherein the genetic alteration is not in one or more of GRM1, GRM2, GRM3, GRM4, GRM5, GRM6, GRM7 or GRM8.
- Claim:
122. The method of claim 112, wherein the subject has the bingeing and/or purging subtype of AN.
- Claim:
123. The method of claim 112, wherein the subject has the restricting subtype of AN.
- Claim:
124. The method of claim 112, wherein the subject is a pediatric or adolescent subject.
- Claim:
125. The method of claim 112, wherein the subject is an adult subject.
- Claim:
126. The method of claim 112, wherein the subject is already taking or is administered one or more of an antidepressant, an anxiolytic or an anti-psychotic.
- Claim:
127. The method of claim 126, wherein the antidepressant is fluoxetine, escitalopram, bupropion, mirtazapine, amitriptyline, imipramine, venlafaxine, sertraline, paroxetine, a tricyclic antidepressant, a selective serotonin reuptake inhibitor, a serotonin and norepinephrine reuptake inhibitor, a norepinephrine and dopamine reuptake inhibitor, or a monoamine oxidase inhibitor.
- Claim:
128. The method of claim 126, wherein the anxiolytic is a barbiturate, pregabalin, or a benzodiazepine.
- Claim:
129. The method of claim 126, wherein the anti-psychotic is olanzapine, quetiapine, aripiprazole or risperidone.
- Claim:
130. The method of claim 113, wherein the fasoracetam is administered in combination with non-pharmaceutical therapy selected from vagus nerve stimulation, repetitive transcranial magnetic stimulation, magnetic seizure therapy, and deep brain stimulation.
- Current International Class:
61; 61; 61; 12
- الرقم المعرف:
edspap.20210267958
Processing Request
No Comments.